Publications by authors named "T L Gindina"
Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience.
Cancers (Basel)
September 2023
Article Synopsis
- This analysis reviewed trends in 5185 hematopoietic cell transplantations (HCT) between 1990 and 2022, including 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) transplants.
- There was a significant improvement in event-free survival (EFS) for both autoHCT and alloHCT over time, attributed to a decrease in relapse rates and non-relapse mortality, respectively.
- Specific survival improvements were noted for various conditions, with autoHCT showing better outcomes in Hodgkin's disease and multiple myeloma, while alloHCT advancements were observed mainly in leukemia and lymphomas.
The posttransplant relapse in Ph-positive ALL increases the risk of death. There is an unmet need for instruments to predict the risk of relapse and plan prophylaxis. In this study, we analyzed posttransplant data by machine learning algorithms.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzes infants with germline KMT2A-g B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving treatment under the MLL-Baby protocol, highlighting outcomes and diagnostic features.
- Out of 139 patients, 39 had KMT2A-g, who were generally older, had lower white blood cell counts, and better survival rates (6-year event-free survival of 74%).
- The findings suggest that while moderate-intensity therapy is effective, patients showing slow response to treatment may benefit from more advanced therapies like targeted or immunotherapies.
The prognostic significance of genetic lesions in T-cell ALL still needs to be elucidated. Karyotyping and FISH were performed in samples from 120 patients with T-cell ALL registered in the trial Moscow-Berlin 2008. Most frequent rearrangements were TLX3 (N = 29; 24%) and TAL1 (N = 18; 15%), followed by KMT2A (N = 6; 5%), TLX1 (N = 5; 4.
View Article and Find Full Text PDFIntroduction: Although a number of studies were published on the efficacy of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis, no large studies prospectively evaluated this strategy in related, unrelated, and haploidentical grafts.
Methods: In this study, GVHD prophylaxis for 57 matched bone marrow (MBM) grafts consisted of single-agent PTCy, for 88 matched PBSC grafts (MPBSC) consisted of PTCy, tacrolimus, and mycophenolate mofetil (MMF) 30 mg/kg, and for 55 mismatched grafts (MMGs) consisted of PTCy, tacrolimus and MMF 45 mg/kg.
Results: The study met the primary endpoint to demonstrate equivalent rates of acute GVHD grade II-IV (11%, 17%,19%, P = .